| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | |
| N795505 | MACKLIN | 硝苯地平 | 10mM in DMSO | 431元/1ml; | 咨询 |
|
| N815087 | MACKLIN | 硝苯地平 | ≥98.0%(HPLC) | 30元/1g; 41元/5g; 75元/25g; 192元/100g; 575元/500g; 2552元/2.5kg; | 咨询 |
|
| N0528 | TCI | Nifedipine | >98.0%(E)(HPLC) | 760元/10G; 1375元/25G; | 咨询 |
基本信息 | 纯度/分析方法 | >98.0%(E)(HPLC) | | 分子式/分子量 | C17H18N2O6 = 346.34 | | 外观与形状(20℃) | 固体 | | 应避免的情况 | 光 | | Reaxys-RN | 497773 | | PubChem物质ID | 87573853 | | SDBS (AIST Spectral DB) | 9750 | | Merck Index (14) | 6528 | | MDL编号 | MFCD00057326 |
技术规格 | Appearance | Light yellow to Yellow to Orange powder to crystal | | Purity(HPLC) | min. 98.0 area% | | Purity(UV-vis method) | min. 98.0 % | | Melting point | 172.0 to 175.0 ℃ | | Solubility in Acetone | almost transparency |
物性(参考值) | 熔点 | 174 ℃ | | 溶解性(可溶于) | 氯仿,丙酮 | | 溶解度(极微溶) | 乙醇 |
安全信息 | 图形或危害标志 |  | | 信号词 | 警告 | | 危险性说明 | H302 : 吞咽有害。
| | 防范说明 | P501 : 将内装物/容器送到批准的废物处理厂处理。
P270 : 使用本产品时不要进食、饮水或吸烟。
P264 : 作业后彻底清洗皮肤。
P301 + P312 + P330 : 如误吞咽：如感觉不适，呼叫急救中心/医生。漱口。
|
相关法规 |
| 307439 | J&K | Nifedipine | 98%, 一种血管舒张化合物, 是钙离子阻断剂 | 366元/5G; 1053元/25G; | 咨询 |
基本信息 | 分子式 | C17H18N2O6 | | 分子量 | 346.30 | | 熔点 | 173-177 | | MDL编码 | MFCD00057326 | | Merck | 14,6528 | | EINECS 编号 | 244-598-3 | | 存储条件 | Store at 2-8℃ |
产品描述 Nifedipine 是一种二氢吡啶类钙离子通道阻滞剂，是有效的血管扩张剂，具有钙拮抗作用。 靶点（IC50 & Targe） Calcium Channel CAM Potassium Channel 体外研究 在培养的人冠状动脉内皮细胞中，Nifedipine显著浓度依赖性增加eNOS蛋白表达。[1] Nifedipine拮抗整个心血管系统中的L-型钙离子通道，也阻断Kv通道，这是相同的超基因家族的成员。[2] 在血管平滑肌细胞（VSMC）中，Nifedipine剂量依赖性降低(3)H-胸苷掺入，总细胞蛋白含量以及磷酸化的细胞外信号调节蛋白激酶（ERK）1/2，丝裂原活化蛋白激酶激酶的水平（MEK）1/2，和Pyk2的磷酸化。在VSMC和球囊损伤胸主动脉血管VSMC中，Nifedipine剂量依赖性抑制增殖细胞核抗原（PCNA）的水平。[3] 体内研究 在大鼠中，Nifedipine（3 毫克/千克）略微降低的收缩和/或舒张期血压的水平或增加的心脏速率。[3] 在脉络膜小动脉平滑肌中，Nifedipine（1 μM）产生存储操作途径的最大抑制。[4] 在大鼠受伤粘膜中，Nifedipine（20和40 毫克/千克）显着阻止盐酸加乙醇诱导的胃粘膜损伤并增加的硫代巴比妥酸反应性物质。在大鼠溃疡粘膜中，Nifedipine（20和40 毫克/千克）剂量依赖性地促进溃疡愈合并抑制硫代巴比妥酸反应性物质的增加。 [5] 参考文献 [1] Ding Y, et al. J Pharmacol Exp Ther,?000, 292(2), 606-609. [2] Zhang X, et al. J Pharmacol Exp Ther,?997, 281(3), 1247-1256. [3] Hirata A, et al. Br J Pharmacol,?000, 131(8), 1521-1530. [4] Curtis TM, et al. J Physiol,?001, 532(Pt 3), 609-623. [5] Suzuki Y, et al. Jpn J Pharmacol,?998, 78(4), 435-441. 安全信息 | 图形或危害标志 | | | 提示语 | Warning | | 危险说明 | H302 | | 防范说明 | P262 | | WGK | 1 | | RTECS | US7975000 |
|
| C32927 | Alfa Aesar | Nifedipine | | 844元/1g; 2668元/5g; 13682元/25g; | 咨询 |
基本信息 Ref#
32927 MDL
57326 分子式
C17 H18 N2 O6 分子量
346.3 形态
Powder |
| R12062 | Alfa Aesar | Nifedipine,1000ppm | | 440元/1ml; | 咨询 |
|
| R11020 | Alfa Aesar | Nifedipine Standard solution | 100ppm | 210元/1ml; | 咨询 |
|
| N7634 | Sigma-Aldrich | Nifedipine | ≥98% (HPLC), powder | 580.55元/1 G; 2555.94元/5 G; 3862.87元/10 G; 5273.86元/25 G; | 咨询 |
产品说明 应用 硝苯地平被用于： - 评估其对豚鼠小肠R-型钙通道中肌间神经元钙电流的影响
- 评估L型钙通道阻滞剂对胆碱能和多巴胺能神经元的神经保护作用
- 确定硝苯地平(抗高血压药物)与降糖药共同给药对人脐静脉细胞(HUVEC)的影响
包装 1, 5, 10, 25 g in glass bottle 生化/生理作用 硝苯地平是一种L型Ca2+ 通道阻滞剂； 可诱导人成胶质细胞瘤细胞凋亡。硝苯地平具有神经保护作用，可保护黑质。硝苯地平具有抗氧化作用。硝苯地平可下调炎性细胞因子，如巨噬细胞炎症蛋白-2(MIP-2)、肿瘤坏死因子-α(TNF-α)。硝苯地平具有抗高血压作用。硝苯地平可抑制腺苷A2a受体(ADORA2A)基因的胞外区。 特点和优势 该化合物由 Bayer开发。想浏览其他制药公司开发的化合物和已批准药物/候选药物目录， 请单击此处。
该化合物在受体分类和信号转导手册的 钙通道 和 环核苷酸门控(CNG)和超极化激活的环核苷酸门控(HCN)通道 页面上有详细描述。如需浏览其他手册页面，请点击此处。
该化合物是ADME Tox和环核苷酸研究的特色产品。发现更多 ADME Tox 和 环核苷酸 的特色产品。了解更多有关用于其他研究领域的生物活性小分子的信息，请访问sigma.com/discover-bsm。 其他说明 Scripps Center for Metabolomics(斯克里普斯代谢组学中心)独立生成的串联质谱数据，可以PDF格式查看或下载。N7634.pdf 经过测试的代谢物在Scripps Center for Metabolomics(斯克里普斯代谢组学中心) METLIN代谢物数据库有重点介绍。更多信息请见sigma.com/metlin。 基本信息 | 经验(实验)分子式 | C17H18N2O6 | | 分子量 | 346.33 | | EC 号 | 244-598-3 | | MDL编号 | MFCD00057326 | | PubChem化学物质编号 | 24277855 | | NACRES | NA.77 |
产品性质 | 质量水平 | 200 | | 测定 | ≥98% (HPLC) | | 形式 | powder | | 颜色 | yellow | | 溶解性 | DMSO: soluble
ethanol: soluble | | 创始人 | Bayer | | 储存温度 | 2-8℃ | | SMILES string | COC(=O)C1=C(C)NC(C)=C(C1c2ccccc2[N+]([O-])=O)C(=O)OC | | InChI | 1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3 | | InChI key | HYIMSNHJOBLJNT-UHFFFAOYSA-N | | Gene Information | human ... ADORA2A(135), ADORA3(140), CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779), CACNA2D1(781), CYP1A2(1544), KCNH1(3756), TTR(7276)
mouse ... Cacna1c(12288)
rat ... Adora1(29290), Adora2a(25369), Cacna1c(24239), Cacna1d(29716), Kcnj1(24521), Kcnn4(65206), Tbxas1(24886) |
安全信息 | 象形图 | | | 警示用语： | Warning | | 危险声明 | H302 | | 预防措施声明 | P264 - P270 - P301 + P312 + P330 - P501 | | 危险分类 | Acute Tox. 4 Oral | | 储存分类代码 | 13 - Non Combustible Solids | | WGK | WGK 1 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable | | 个人防护装备 | dust mask type N95 (US), Eyeshields, Gloves |
|
| PHR1290 | Supelco | Nifedipine | Pharmaceutical Secondary Standard; Certified Reference Material | 1359.83元/1 G; | 咨询 |
产品说明 一般描述 Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Nifedipine belongs to the class of calcium channel antagonist drugs and finds a wide use as an antihypertensive and an antianginal agent. It can also be used as a coronary vasodilator. 应用 These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
Nifedipine may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations and plasma samples by spectrophotometry and chromatography techniques. 分析说明 These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available. 其他说明 This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis. 附注 To see an example of a Certificate of Analysis for this material enter LRAA0488 in the slot below. This is an example certificate only and may not be the lot that you receive. 基本信息 | 经验(实验)分子式 | C17H18N2O6 | | 分子量 | 346.33 | | EC 号 | 244-598-3 | | MDL编号 | MFCD00057326 | | PubChem化学物质编号 | 329823282 | | NACRES | NA.24 |
产品性质 | 质量水平 | 300 | | 等级 | certified reference material
pharmaceutical secondary standard | | CofA | current certificate can be downloaded | | technique(s) | HPLC: suitable
gas chromatography (GC): suitable | | application(s) | pharmaceutical (small molecule) | | 格式 | neat | | 药典可追溯性 | traceable to BP 462
traceable to PhEur N0750000
traceable to USP 1463508 | | 储存温度 | 2-30℃ | | SMILES string | COC(=O)C1=C(C)NC(C)=C(C1c2ccccc2[N+]([O-])=O)C(=O)OC | | InChI | 1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3 | | InChI key | HYIMSNHJOBLJNT-UHFFFAOYSA-N | | Gene Information | human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779) |
安全信息 | 象形图 | | | 警示用语： | Warning | | 危险声明 | H302 | | 危险分类 | Acute Tox. 4 Oral | | 储存分类代码 | 13 - Non Combustible Solids | | WGK | WGK 1 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable |
|
| 1463508 | USP | Nifedipine | United States Pharmacopeia (USP) Reference Standard | 2633.96元/125 MG; | 咨询 |
产品说明 分析说明 These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind. 其他说明 USP issued SDS can be found here.
Sales restrictions may apply. 基本信息 | 经验(实验)分子式 | C17H18N2O6 | | 分子量 | 346.33 | | EC 号 | 244-598-3 | | MDL编号 | MFCD00057326 | | PubChem化学物质编号 | 329750558 | | NACRES | NA.24 |
产品性质 | 等级 | pharmaceutical primary standard | | manufacturer/tradename | USP | | application(s) | pharmaceutical (small molecule) | | 格式 | neat | | SMILES string | COC(=O)C1=C(C)NC(C)=C(C1c2ccccc2[N+]([O-])=O)C(=O)OC | | InChI | 1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3 | | InChI key | HYIMSNHJOBLJNT-UHFFFAOYSA-N | | Gene Information | human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779) |
安全信息 | 象形图 | | | 警示用语： | Warning | | 危险声明 | H302 | | 预防措施声明 | P301 + P312 + P330 | | 危险分类 | Acute Tox. 4 Oral | | 储存分类代码 | 13 - Non Combustible Solids | | WGK | WGK 1 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable |
|
| N0750000 | | Nifedipine | European Pharmacopoeia (EP) Reference Standard | 1259.15元/ ; | 咨询 |
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia. 包装 Unit quantity: 50 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue. 注意 Please find SDS provided by EDQM here.. 其他说明 Sales restrictions may apply. 基本信息 | 经验(实验)分子式 | C17H18N2O6 | | 分子量 | 346.33 | | MDL编号 | MFCD00057326 | | PubChem化学物质编号 | 329818455 | | NACRES | NA.24 |
产品性质 | 等级 | pharmaceutical primary standard | | manufacturer/tradename | EDQM | | application(s) | pharmaceutical (small molecule) | | 格式 | neat | | SMILES string | COC(=O)C1=C(C)NC(C)=C(C1c2ccccc2[N+]([O-])=O)C(=O)OC | | InChI | 1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3 | | InChI key | HYIMSNHJOBLJNT-UHFFFAOYSA-N | | Gene Information | human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779) |
安全信息 | 象形图 | | | 警示用语： | Warning | | 危险声明 | H302 | | 预防措施声明 | P301 + P312 + P330 | | 危险分类 | Acute Tox. 4 Oral | | 储存分类代码 | 13 - Non Combustible Solids | | WGK | WGK 1 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable |
|
| 481981 | Sigma-Aldrich | Nifedipine-CAS 21829-25-4-Calbiochem | Relatively selective blocker of L-type Ca2+ channels. | 1113.94元/250 MG; | 咨询 |
产品说明 一般描述 Relatively selective blocker of L-type Ca2+ channels. One of the most extensively studied blockers of 1,4-dihydropyridine-type Ca2+ channels, and a pharmacologically-useful vasodilator. Induces apoptosis in human glioblastoma cells.
Relatively selective blocker of L-type Ca2+ channels. One of the most extensively studied Ca2+ channel blockers of 1,4-dihydropyridine-type and a pharmacologically useful vasodilator. Induces apoptosis in human glioblastoma cells. 包装 250 mg in Plastic ampoule 生化/生理作用 Product does not compete with ATP.
Reversible: no
Primary Target
L-type Ca2+ channels
Cell permeable: no 警告 Toxicity: Harmful & Carcinogenic / Teratogenic (E) 重悬 Following reconstitution, refrigerate (-20°C). Stock solutions are stable for up to 3 months at -20°C. 其他说明 Reid, K., et al. 1997. J. Pharmacol. Exp. Ther. 283, 993.
Kondo, S., et al. 1995. J. Neurosurg.82, 469.
Antkiewicz-Michaluk, L., et al. 1994. Eur. J. Pharmacol. 254, 9.
Calabresi, P., et al. 1994. J. Neurosci. 14, 4871.
Akman, M.S., et al. 1993. Endocrinology132, 1286.
Cirillo, M., et al. 1993. Circ. Res.72, 847.
Young, R.J., et al. 1993. Biochim. Biophys. Acta1146, 81.
Janis, R., et al. 1987. Adv. Drug Res.16, 311. 法律信息 CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany 基本信息 | 经验(实验)分子式 | C17H18N2O6 | | 分子量 | 346.33 | | MDL编号 | MFCD00057326 |
产品性质 | 质量水平 | 100 | | 测定 | ≥98% (UV) | | 形式 | solid | | manufacturer/tradename | Calbiochem® | | 储存条件 | OK to freeze
protect from light | | 颜色 | yellow | | 溶解性 | DMSO: soluble
ethanol: soluble | | 运输 | ambient | | 储存温度 | 10-30℃ | | InChI | 1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3 | | InChI key | HYIMSNHJOBLJNT-UHFFFAOYSA-N |
安全信息 | 象形图 | | | 警示用语： | Warning | | 危险声明 | H302 | | 预防措施声明 | P264 - P270 - P301 + P312 - P501 | | 危险分类 | Acute Tox. 4 Oral | | 储存分类代码 | 11 - Combustible Solids | | WGK | WGK 1 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable |
|
| BP462 | | Nifedipine | British Pharmacopoeia (BP) Reference Standard | 1760.91元/100 MG; | 咨询 |
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia. 包装 Unit quantity: 100 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia 其他说明 Sales restrictions may apply. 基本信息 | 经验(实验)分子式 | C17H18N2O6 | | 分子量 | 346.33 | | EC 号 | 244-598-3 | | MDL编号 | MFCD00057326 | | NACRES | NA.24 |
产品性质 | 等级 | pharmaceutical primary standard | | manufacturer/tradename | BP | | 格式 | neat | | 储存温度 | 2-8℃ | | SMILES string | COC(=O)C1=C(C)NC(C)=C(C1c2ccccc2[N+]([O-])=O)C(=O)OC | | InChI | 1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3 | | InChI key | HYIMSNHJOBLJNT-UHFFFAOYSA-N | | Gene Information | human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779) |
安全信息 | 象形图 | | | 警示用语： | Warning | | 危险声明 | H302 | | 预防措施声明 | P301 + P312 + P330 | | 危险分类 | Acute Tox. 4 Oral | | 储存分类代码 | 13 - Non Combustible Solids | | WGK | WGK 1 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable |
|
| 047202 | Fluorochem | Nifedipine | 98% | 286元/1g; 704元/5g; 1298元/10g; 2244元/25g; | 咨询 |
基本信息 | CAS Number | 21829-25-4 | | MDL Number | MFCD00057326 | | Melting Point | 174℃ |
安全信息 | 图形或危害标志 | | | 危险性说明 | H302: Harmful if swallowed.
H315: Causes skin irritation.
H319: Causes serious eye irritation.
H335: May cause respiratory irritation.
| | 防范说明 | P233: Keep container tightly closed.
P260: Do not breathe .
P261: Avoid breathing
P264: Wash hands thoroughly after handling.
P270: Do not eat, drink or smoke when using this product.
P271: Use only outdoors or in a well-ventilated area.
P280: Wear .
P301 + P312: IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell.
P302 + P352: IF ON SKIN: Wash with plenty of soap and water.
P304: IF INHALED: .
P304 + P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P312: Call a POISON CENTER or doctor/physician if you feel unwell.
P321: Specific treatment (see . on this label).
P330: Rinse mouth.
P332 + P313: If skin irritation occurs: Get medical advice/ attention.
P337 + P313: If eye irritation persists: Get medical advice/attention.
P340: Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P362: Take off contaminated clothing and wash before reuse.
P403: Store in a well-ventilated place.
P403 + P233: Store in a well-ventilated place. Keep container tightly closed.
P405: Store locked up.
P501: Dispose of contents/container to local regulations.
|
|
m.cnreagent.com